Tianjin Lisheng PharmaceuticalLtd Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Tianjin Lisheng PharmaceuticalLtd has been growing earnings at an average annual rate of 22.3%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 4.8% per year. Tianjin Lisheng PharmaceuticalLtd's return on equity is 3.7%, and it has net margins of 14.9%.
Belangrijke informatie
22.3%
Groei van de winst
22.2%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 10.9% |
| Inkomstengroei | -4.8% |
| Rendement op eigen vermogen | 3.7% |
| Nettomarge | 14.9% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Tianjin Lisheng PharmaceuticalLtd geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 1,265 | 188 | 453 | 119 |
| 30 Jun 24 | 1,240 | 374 | 448 | 91 |
| 31 Mar 24 | 1,182 | 374 | 425 | 103 |
| 31 Dec 23 | 1,153 | 362 | 429 | 102 |
| 30 Sep 23 | 1,156 | 324 | 441 | 91 |
| 30 Jun 23 | 1,189 | 112 | 466 | 103 |
| 31 Mar 23 | 1,176 | 98 | 467 | 100 |
| 01 Jan 23 | 1,147 | 94 | 449 | 102 |
| 30 Sep 22 | 1,158 | 137 | 481 | 111 |
| 30 Jun 22 | 1,119 | 133 | 469 | 107 |
| 31 Mar 22 | 1,071 | 128 | 450 | 101 |
| 01 Jan 22 | 1,092 | 122 | 466 | 101 |
| 30 Sep 21 | 1,061 | 27 | 448 | 94 |
| 30 Jun 21 | 1,114 | 13 | 482 | 93 |
| 31 Mar 21 | 1,136 | 10 | 510 | 78 |
| 31 Dec 20 | 1,141 | 9 | 547 | 73 |
| 30 Sep 20 | 1,321 | 133 | 643 | 82 |
| 30 Jun 20 | 1,374 | 156 | 686 | 90 |
| 31 Mar 20 | 1,513 | 178 | 773 | 102 |
| 31 Dec 19 | 1,615 | 188 | 813 | 120 |
| 30 Sep 19 | 1,613 | 215 | 839 | 75 |
| 30 Jun 19 | 1,589 | 205 | 838 | 74 |
| 31 Mar 19 | 1,544 | 188 | 798 | 87 |
| 31 Dec 18 | 1,504 | 185 | 769 | 92 |
| 30 Sep 18 | 1,366 | 122 | 707 | 129 |
| 30 Jun 18 | 1,273 | 107 | 564 | 188 |
| 31 Mar 18 | 1,138 | 117 | 479 | 144 |
| 01 Jan 18 | 1,029 | 117 | 420 | 101 |
| 30 Sep 17 | 975 | 137 | 348 | 85 |
| 30 Jun 17 | 915 | 125 | 394 | 0 |
| 31 Mar 17 | 896 | 114 | 386 | 0 |
| 31 Dec 16 | 847 | 116 | 350 | 0 |
| 30 Sep 16 | 792 | 74 | 327 | 0 |
| 30 Jun 16 | 769 | 77 | 304 | 0 |
| 31 Mar 16 | 779 | 110 | 295 | 0 |
| 31 Dec 15 | 775 | 114 | 291 | 0 |
| 30 Sep 15 | 762 | 104 | 301 | 0 |
| 30 Jun 15 | 759 | 104 | 307 | 0 |
| 31 Mar 15 | 725 | 75 | 301 | 0 |
| 31 Dec 14 | 774 | 93 | 323 | 0 |
| 30 Sep 14 | 851 | 129 | 337 | 0 |
| 30 Jun 14 | 925 | 178 | 345 | 0 |
| 31 Mar 14 | 1,016 | 252 | 365 | 0 |
| 31 Dec 13 | 1,044 | 293 | 351 | 0 |
Kwaliteitswinsten: 002393 has high quality earnings.
Groeiende winstmarge: 002393's current net profit margins (14.9%) are lower than last year (28%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 002393's earnings have grown significantly by 22.3% per year over the past 5 years.
Versnelling van de groei: 002393's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 002393 had negative earnings growth (-41.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
Rendement op eigen vermogen
Hoge ROE: 002393's Return on Equity (3.7%) is considered low.